Leukemias | Mark Levis, MD, PhD

1:12:32
 
Share
 

Manage episode 230910635 series 1464173
By Dr Neil Love. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.

Acute Leukemias Update — Part 1: Our interview with Dr Levis highlights the following topics as well as cases from his practice:

  • Molecular profiling in the diagnosis and treatment of acute myeloid leukemia (AML) (00:00)
  • Management of AML with p53 mutations (03:13)
  • Efficacy of hypomethylating agents with venetoclax in older patients with AML (06:41)
  • Therapeutic options for patients with AML and FLT3 mutations (10:31)
  • Monitoring and management of venetoclax-associated tumor lysis syndrome (13:06)
  • Case: A 62-year-old woman who presents with fatigue and bleeding gums is diagnosed with AML with FLT3 and NPM1 mutations (16:08)
  • Role of the FLT3 pathway in myeloid cell development and types of FLT3 mutations (17:10)
  • Impact of FLT3 mutations on therapeutic decision-making (21:01)
  • Activity of midostaurin in newly diagnosed AML with a FLT3 mutation (23:48)
  • BMT CTN 1506: A Phase III trial of gilteritinib as maintenance therapy after allogeneic transplant for patients with AML and FLT3-ITD mutations (25:20)
  • Case: A 60-year-old man with AML and a FLT3-ITD mutation receives gilteritinib with standard 7 + 3 chemotherapy induction followed by allotransplant and maintenance gilteritinib on a clinical trial (27:20)
  • Similarities and differences among midostaurin, quizartinib and gilteritinib (28:58)
  • Case: A 63-year-old man with refractory AML and an IDH2 mutation receives enasidenib and develops differentiation syndrome (31:46)
  • Biologic rationale for targeting IDH1/2 mutations and activity of ivosidenib or enasidenib in patients with relapsed/refractory AML (35:57)
  • Efficacy and side effects of CPX-351 (liposomal cytarabine/daunorubicin) in patients with AML (40:46)
  • Case: A 28-year-old obese man with acute lymphoblastic leukemia (ALL) and an MLL rearrangement develops hepatic toxicity after treatment with the Berlin-Frankfurt-Munster pediatric-inspired regimen containing L-asparaginase (43:01)
  • Mechanism of action, activity and tolerability of blinatumomab for ALL (46:38)
  • Neurologic side effects associated with blinatumomab (49:03)
  • Use of blinatumomab for minimal residual disease-positive ALL (51:53)
  • Optimal use of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive ALL (53:30)
  • Case: A 41-year-old woman receives chimeric antigen receptor (CAR) T-cell therapy for relapsed ALL (58:37)
  • Role of CAR T-cell therapy in the management of ALL (1:01:31)
  • Use of the antibody-drug conjugates gemtuzumab ozogamicin and inotuzumab ozogamicin for acute leukemias (1:07:42)
  • Activity of gemtuzumab ozogamicin in patients with high-risk acute promyelocytic leukemia (APL) (1:10:30)

Select publications

2183 episodes